Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LIXT.............................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering
July 9, 2025
Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes an exercise price of $0.00001.
The Company received gross proceeds of approximately $1.5 million. The net proceeds, together with the Company’s existing cash, will be used for general corporate purposes and working capital.
“This transaction reflects our continued focus on aligning innovative biotech companies with the strategic capital they need to advance breakthrough therapies,” said John Lowry, CEO of Spartan Capital Securities. “We are pleased to support Lixte Biotechnology Holdings, LLC in this important stage of their clinical development and look forward to seeing the impact of their work in the oncology space.”
Lixte was represented by TroyGould PC, while Spartan Capital Securities was represented by Kaufman & Canoles, P.C.
The offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with and declared effective by the U.S. Securities and Exchange Commission on May 2, 2024. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spartan Capital Securities, LLC
Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients’ financial goals.
For more information, visit www.spartancapital.com.
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing cancer therapies based on novel biological pathways. Its lead compound, LB-100, a first-in-class PP2A inhibitor, has shown promise in enhancing the effectiveness of chemotherapy and immunotherapy. Clinical trials are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
For more information, visit www.lixte.com.
Contact:
Spartan Capital Securities, LLC
45 Broadway, 19th Floor
New York, NY 10006
investmentbanking@spartancapital.com
https://ih.advfn.com/stock-market/NASDAQ/lixte-biotechnology-LIXT/stock-news/96402861/spartan-capital-securities-llc-serves-as-placemen
$LIXT
LIXT......................................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
LIXT..............................................................................................p/m
LIXT...................................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
LIXT.............................................................a/h
LIXT.......................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
LIXT............................................https://stockcharts.com/h-sc/ui?s=lixt&p=W&b=5&g=0&id=p86431144783
.................thx..........................
$1.06 + 54% ...Company no longer intends to pursue a public offering under the Registration Statement at this time PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange no longer intends to pursue a public offering under the Registration Statement at this time ommission (the “SEC”) of the Company’s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as th
Early withdrawal has its benefits
$3.29+ 44%
LIXT 1.89 + 44%
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Some $60k-$90k buys,institutional buys starting?12%currently,up2%
July 17, 2023
8:30 am ET
Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Globe Newswire
Amazing to watch 1.64 to flat same day. SEC sleeps again
LIXT......................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783
LIXT NEWS 1.50'S
MAYBE OFFERING NEXT
WE KNOW THEY NEED IT= $$$$$$$$$$$$$$$$$$$$
LIXT: Just more "HYPER-STIMULATION" of the PRICE of their stock!! (HA-HA!!!)
1.01 WAS LOD SUCH A SHAME
LIXT 1.34X1.36 could go again, if volume comes in and squeezes=
$LIXT here is the technical chart with the inside bar on daily..... i buy the dip never the rip +100 or 200% works better pic.twitter.com/k6IlsHMUIy
— Antonio Costa (@ACInvestorBlog) February 8, 2023
1.29 I think they want people to chase a pop before the company wakes up and announces an offer
thats what I think
LIXT trying 1.30 break after just dumped to 1.16 again
all these are PD's controlled by robots
LIXT: And gettin' even LOWER in the A.F. routine, Boss.
PS: But SOUN, BBAI, et al., all UP a bit behind that Bing Search Engine news & 'AI Voice' stuff.
LIXT: Indeed, G-2-G!! Evidently, Peeps are getting --- as they should be --- rather JADED behind the obligatory, NEXT-GREAT-CANCER-CURE-OF-THE-DAY, routines!! And the subject one here, is nowhere near the HUMAN Phase studies level. And, their PR was FUNNY, to boot!!! E.g., stimulate, feed, promote, & otherwise AUGMENT the Cancer cells entire cellular STRUCTURES to such extreme extent, that they FORGET that they are indeed CANCER cells in the FIRST PLACE --- and then they will act NORMAL, & NOT want to metastasize anywhere!!!!! Where they KIDDING us all??????
LIXT 2.56 @ 3:30 NOW 1.50
PRETTY SICK...NO???
ITS NOT LIKE THERE WAS AN OFFERING FOR CHEAP SAKES
Thx for the heads up… got me 3k just below 2$ but stop is in
I belive this will see a nice move near therm
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
98
|
Created
|
03/18/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |